Running Point Capital Advisors, LLC Avrobio, Inc. Transaction History

Running Point Capital Advisors, LLC

  • $256 Million
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 12, 2022
BUY
$1.29 - $4.04 $12,900 - $40,400
10,000 New
10,000 $13,000

Others Institutions Holding AVRO

# of Institutions
1
Shares Held
559K
Call Options Held
0
Put Options Held
0
View Full List

About AVROBIO, Inc.

AVRO Quotes by TradingView
  • Ticker AVRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,773,900
  • Description
  • AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...
More about AVRO
Track This Portfolio

Track Running Point Capital Advisors, LLC Portfolio

Follow Running Point Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Running Point Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Running Point Capital Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email